Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) – Cantor Fitzgerald issued their FY2021 EPS estimates for Clarus Therapeutics in a report issued on Monday, September 20th. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings per share of ($19.26) for the year. Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Clarus Therapeutics’ FY2022 earnings at ($2.67) EPS.
Separately, Oppenheimer started coverage on Clarus Therapeutics in a research report on Monday. They issued an “outperform” rating and a $12.00 price target on the stock.
Clarus Therapeutics Company Profile
Clarus Therapeutics Inc is a specialty pharmaceutical company which provide solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women. The Company’s commercial product includes JATENZO(R). Clarus Therapeutics Inc, formerly known as Blue Water Acquisition Corp., is based in NORTHBROOK, Ill.
Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.